PureTech Health (LON:PRTC) Trading Up 14.2% - Should You Buy?

Key Points

• Shares of PureTech Health surged by 14.2% on Friday, closing at GBX 121.50 ($1.64) after trading as high as GBX 123.80 ($1.67).
• The stock experienced a significant trading volume increase, with 9,013,305 shares exchanged, marking a 1,053% rise from the average session volume.
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1 per share, indicating confidence in the company's performance.

Shares of PureTech Health plc (LON:PRTC - ) shot up 14.2% during mid-day trading on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares traded hands during trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 14.2%

The stock has a market capitalization of £293.65 million, a price-to-earnings ratio of 714.71 and a beta of 1.02. The company's 50 day moving average is GBX 129.64 and its 200 day moving average is GBX 129.95. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

Insider Activity

In other PureTech Health news, insider Bharatt Chowrira acquired 167,739 shares of the company's stock in a transaction dated Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, for a total transaction of £1,677.39. Corporate insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.